The US Patent and Trademark Office has issued US Patent No. 10,874,818, titled "Aerosol Delivery System," covering technology used in the delivery of Windtree Therapeutics' Aerosurf aerosolized KL4 surfactant, Windtree said. The company redesigned the aerosol delivery system (ADS) platform prior to initiating Phase 3 studies of Aerosurf after problems with the … [Read more...] about Windtree gets US patent covering its aerosol delivery system
News
Tonix licenses intranasal oxytocin for the treatment of Prader-Willi syndrome
Tonix Pharmaceuticals announced that it has licensed technology related to oxytocin-based therapies for the treatment of Prader-Willi syndrome and non-organic failure to thrive disease from the French National Institute of Health and Medical Research (Inserm). According to Tonix, patents included in the license provide exclusivity through 2031 in the US and Europe. … [Read more...] about Tonix licenses intranasal oxytocin for the treatment of Prader-Willi syndrome
Study finds that inhaled budesonide can reduce severity of and speed recovery from COVID-19
A Phase 2 study of inhaled budesonide for the treatment of COVID-19 found that patients who received 800 mcg twice daily plus standard of care within 7 days after first experiencing symptoms had a 90% reduced risk of urgent medical care or hospital admission compared to patients who did not get inhaled budesonide. The STOIC study enrolled 146 adult patients with early … [Read more...] about Study finds that inhaled budesonide can reduce severity of and speed recovery from COVID-19
SarcoMed USA acquires worldwide license for Protalix BioTherapeutics’s inhaled alidornase alfa
According to Protalix BioTherapeutics, the company has signed an agreement with SarcoMed USA giving SarcoMed exclusive worldwide license agreement for Protalix's PRX-110 inhaled alidornase alfa for the treatment of respiratory diseases including pulmonary sarcoidosis and pulmonary fibrosis. SarcoMed's lead candidate, SM001, is an inhaled DNase 1 formulation that the … [Read more...] about SarcoMed USA acquires worldwide license for Protalix BioTherapeutics’s inhaled alidornase alfa
Hangzhou Chance Pharmaceuticals gets rights to Aerami’s inhaled imatinib for PAH in the Chinese market
Hangzhou Chance Pharmaceuticals is paying an undisclosed amount up front, plus milestone payments and royalties, to acquire the rights to develop and commercialize Aerami Therapeutics' AER-901 inhaled imatinib for the treatment of pulmonary arterial hypertension in China, Hong Kong, Macau, and Taiwan, Aerami has announced. Aerami will continue to develop AER-901 for … [Read more...] about Hangzhou Chance Pharmaceuticals gets rights to Aerami’s inhaled imatinib for PAH in the Chinese market
Herantis partners with Nanoform on intranasal biologics formulation projects
Herantis Pharma has signed an agreement with nanoparticle technology company Nanoform Finland to try out Nanoform's biologics nanoparticle technology for intranasal formulations of CDNF (cerebral dopamine neurotrophic factor). Nanoform launched its nanoparticle technology for biologics in November 2020. Herantis is developing CDNF for the treatment of Parkinson’s … [Read more...] about Herantis partners with Nanoform on intranasal biologics formulation projects
Hovione Technology gets patent for new particle size analysis method
Hovione Technology, a subsidiary of CDMO Hovione, announced that it has been granted a patent on a new method of particle size analysis that provides improved sample preparation for more accurate measurements and better repeatability. Hovione Technology primarily focuses on dry powder inhaler devices, including the 8Shot large dose DPI, the TwinMax DPI, the Papillon … [Read more...] about Hovione Technology gets patent for new particle size analysis method
EC approves expanded indication for Spravato esketamine nasal spray
According to Janssen, the company's Spravato esketamine nasal spray has been approved by the EC as an add-on to oral antidepressants for adult patients with major depressive disorder (MDD) "as acute short term treatment, for the rapid reduction of depressive symptoms, which according to clinical judgment constitute a psychiatric emergency." The EMA’s Committee … [Read more...] about EC approves expanded indication for Spravato esketamine nasal spray
NeuroRx initates Phase 2/3 trial of nebulized Zyesami aviptadil for the treatment of COVID-19
NeuroRx announced that it has initiated a Phase 2/3 clinical trial of nebulized Zyesami aviptadil (RLF-100) for the treatment of severe COVID-19. In August 2020, NeuroRx announced that the FDA had cleared an IND for the trial, which is being led by researchers from the University of California Irvine's UCI Health. Principal investigator Richard Lee, Interim Chief … [Read more...] about NeuroRx initates Phase 2/3 trial of nebulized Zyesami aviptadil for the treatment of COVID-19
AuraVax licenses intranasal vaccine technology from University of Houston
AuraVax Therapeutics, which is developing an intranasal vaccine against COVID-19, announced that it has acquired an exclusive license for IP related to intranasal respiratory vaccine technology and STING agonist technology from the University of Houston. Earlier this year, the company announced that it had licensed liposomal STING agonist technology from Massachusetts … [Read more...] about AuraVax licenses intranasal vaccine technology from University of Houston